VMD Earnings Prediction
The chart below shows how VMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VMD sees a -2.18% change in stock price 10 days leading up to the earnings, and a +1.82% change 10 days following the report. On the earnings day itself, the stock moves by +0.42%. This data can give you a slight idea of what to expect for the next quarter's release.
VMD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
58.00M
17.41%
5.53%
Gross Margin
58.66%
-3.87%
-0.85%
Operating Margin
8.89%
-2.09%
59.03%
Net Margin
6.73%
13.87%
150.19%
EPS
0.10
42.86%
150.00%
No Data Available
VMD Earnings Analysis
Viemed Healthcare, Inc. Common Shares Corporation (VMD.O) Earnings Conference Call
Positive
Record Net Revenue Achievement: 1. Record Net Revenue: Viemed achieved a record net revenue of $58 million in Q3 2024, exceeding the top end of guidance and reflecting strong year-over-year and sequential growth.
Vent Patient Growth: 2. Growth in Vent Patients: The company reported a 4.3% sequential increase in active vent patients, with a total increase of over 400 patients in both Q2 and Q3, indicating a positive outlook for future quarters.
EBITDA Margin Improvement: 3. Improved EBITDA Margin: The EBITDA margin for Q3 2024 improved to 24.1%, up from 23.3% in the previous quarter, showcasing effective cost management and operational efficiencies.
Sleep Therapy Patient Growth: 4. Increase in Sleep Therapy Patients: Viemed increased its sleep therapy patient count by 11% sequentially to 19,478, alongside a 9.7% sequential increase in resupply orders, indicating strong demand in the sleep business.
Cash Reserves Increase: 5. Strong Cash Position: The company built up cash by $2.5 million to $11.3 million as of quarter end, while also paying down $2 million on its line of credit, enhancing its financial flexibility for future growth opportunities.
Negative
Gross Margin Decline: 1. Declining Gross Margin: The gross margin decreased year-over-year to 59.3%, attributed to a change in product and service mix as sleep, oxygen, and staffing businesses grew at a faster rate.
CapEx Investment in Equipment: 2. High CapEx Spending: The company reported a gross CapEx of approximately $11 million for the quarter, with net cash CapEx at $5 million, indicating significant investment in respiratory equipment amidst ongoing challenges with recalled ventilators.
Rising SG&A Expenses: 3. Increased SG&A Expenses: Despite a reduction in SG&A as a percentage of revenue to 46%, the absolute expenses remain high, reflecting ongoing investments in new sales talent and operational improvements.
Organic Revenue Focus: 4. Limited Revenue Growth from Acquisitions: The revenue increase of $1.1 million year-over-year was primarily organic, with only $327,000 attributed to acquired revenue, highlighting a reliance on organic growth amidst a challenging acquisition environment.
Regulatory Change Uncertainty: 5. Uncertainty in Regulatory Changes: The potential recovery of the 75-25 reimbursement relief remains uncertain, with only legislative support noted, which could impact future financial performance if not realized.
VMD FAQs
How does VMD typically perform around its earnings report dates?
Is Viemed Healthcare, Inc. (VMD) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VMD Earning Call Sentiment
Viemed Healthcare, Inc. (VMD) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VMD.O
0%Positive
The earnings call shows positive financial performance with revenue growth and improved margins. However, regulatory risks and competitive pressures pose potential challenges. The Q&A reveals some lack of clarity in management responses, particularly regarding the replacement of recalled ventilators. Positive aspects like the Philips buyback program and improved cash position are offset by uncertainties in regulatory guidelines and supply chain challenges. The absence of market cap data limits the assessment of stock price sensitivity, leading to a neutral sentiment prediction.
